In this case report we describe an 80-yearold man with sick sinus syndrome (SSS) who developed syncope attacks. The diagnosis of SSS was based on electrocardiographic evidence of markedly prolonged sinus arrests associated with syncope attacks while in hospital. The patient was given cilostazol, an antithrombotic agent that selectively inhibits cyclic nucleotide phosphodiesterase type 3, at a dose of 100 mg twice daily. The syncope attacks ceased, and an electrocardiogram obtained 1 week after the start of cilostazol administration showed no evidence of sinus arrest. The outcome of this case suggests that cilostazol may be useful in patients with syncope attacks due to SSS, although the long-term chronotropic effects of cilostazol need to be evaluated.
Introduction
Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) was approved in 1988 for the treatment of symptoms related to peripheral arterial occlusive disease in Japan. It was approved for the treatment of intermittent claudication in 1999 in the USA and in 2001 in the UK. 1, 2 This agent was originally developed as a selective inhibitor of cyclic nucleotide phosphodiesterase type 3. 1,3 Inhibition of phosphodiesterase type 3 in platelets and vascular smooth muscle cells was expected to produce an anti-platelet effect and vasodilation. Cilostazol is less likely than aspirin to cause a tendency for bleeding since it does not interrupt the adhesion of platelets to the vascular wall during the first step of thrombus formation; 2 it should not noticeably prolong the bleeding time. It has been reported that cilostazol can be safely administered short term to selected patients with third-degree atrioventricular block. 4 In this case report, we describe an 80-yearold man with syncope attacks due to sick sinus syndrome (SSS) in whom a chronotropic effect of cilostazol was observed.
Case report
In December 2003, an 80-year-old male had a sudden-onset episode of dizziness lasting for several seconds. At that time this symptom was not investigated. In January 2004, he began to experience syncope attacks in the absence of obvious provocation. Over the next month the syncope attacks increased in frequency until they were occurring two or three times a week, and the patient was admitted to our medical department in February 2004.
The patient showed no abnormal physical findings, including no neurological focal deficit, except for a mild bradycardia of 52 beats/min. Systolic and diastolic blood pressures were within normal ranges. Amlodipine had already been prescribed to treat hypertension. He had never received other cardioactive drugs, such as β-adrenoceptor blocking agents or digitalis.
There was no history of stroke, psychiatric disorders or epilepsy. Blood tests showed almost normal findings, except for mild renal dysfunction. The results of a magnetic resonance imaging scan of the brain were normal.
The syncope attacks persisted and increased to a frequency of three or four times a day. A monitoring electrocardiogram (ECG) showed a markedly prolonged sinus arrest lasting for 5.8 s; this finding was concurrent with a syncope attack ( Fig. 1A) and suggested a diagnosis of SSS leading to syncope. Cilostazol (Pletal ® , Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan) was administered orally at a dose of 100 mg twice daily. The syncope attacks ceased, and an ECG obtained 1 week after the start of cilostazol administration showed a heart rate of 55 beats/min and no evidence of sinus arrest (Fig. 1B) .
Implantation of a permanent cardiac pacemaker was performed after 2 weeks' treatment with cilostazol, since the longterm chronotropic effects of this drug have not yet been established in such cases.
Discussion
The treatment of SSS usually involves implantation of a cardiac pacemaker. For those patients in whom pacemaker implantation is contraindicated, however, such as those with a tendency for bleeding, an alternative, pharmacological therapy would be of great value. Previous studies have reported that oral administration of theophylline, a phosphodiesterase inhibitor, may be effective in patients with symptomatic sinus bradycardia. 5, 6 Since cilostazol also has an inhibitory action on phosphodiesterase, it may be useful for treating SSS. The effects of cilostazol on intracellular cyclic adenosine monophosphate levels and cellular function have been demonstrated in cardiac ventricular myocytes. 7 Reports on the chronotropic and dromotropic effects of cilostazol in patients 550 J Moriya, T Takahashi, Y Nomura et al. Cilostazol in a patient with sick sinus syndrome and syncope with bradyarrhythmias are rare to date. An increased heart rate induced by the administration of cilostazol has been demonstrated in SSS, atrial fibrillation and Mobitz I second-degree (Wenckebach) atrioventricular block. 8 -11 To the best of our knowledge this is the first report of cilostazol use in a patient with syncope attacks due to SSS, however. The long-term chronotropic and dromotropic effects have not been determined in this patient population. Rapid ventricular tachycardias associated with cilostazol use have been reported as an adverse effect. 12 In summary, we have described an 80-yearold man with syncope attacks resulting from SSS. This diagnosis was based on ECG evidence of markedly prolonged sinus arrests associated with syncope attacks during hospitalization. After oral administration of cilostazol at a dose of 100 mg twice daily was initiated, the syncope attacks ceased. An ECG obtained 1 week later showed no signs of sinus arrest. This case report suggests that cilostazol may be useful in patients with syncope attacks due to SSS, although the long-term chronotropic effects of cilostazol need to be evaluated.
